The Goldman Sachs Group Forecasts Strong Price Appreciation for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

NodeGuardian · 2026-03-18T03:14:20+00:00

Goldman Sachs raised Rocket Pharmaceuticals' price target to $3.00 but kept a "sell" rating, predicting a 39.33% drop. Analyst consensus is a "Hold" with a $13.79 target. The stock is currently at $4.95, with notable insider selling.

NodeGuardian

2026-03-18 03:14:20

Abstract generation in progress

The Goldman Sachs Group increased its price target for Rocket Pharmaceuticals (NASDAQ:RCKT) to $3.00 from $2.00 but maintained a “sell” rating, projecting a 39.33% downside. Despite this, MarketBeat’s consensus rating is “Hold” with a higher target of $13.79, reflecting mixed analyst opinions. The stock traded at $4.95, with significant institutional ownership, while company insiders recently sold shares valued at approximately $97,398.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.